10-Q: Paysign Reports Strong Q1 2026 Growth

Paysign, Inc. announced a significant increase in total revenues and net income for the first quarter of 2026, driven by substantial growth in its pharma and plasma industries segments.

Summary

• Total revenues for the first quarter of 2026 reached $28.04 million, a 50.8% increase compared to $18.60 million in the same period of 2025.
• Net income surged to $5.44 million ($0.09 per diluted share) from $2.59 million ($0.05 per diluted share) in Q1 2025.
• Gross profit increased by 55.8% to $18.22 million, with gross margin improving to 65.0% from 62.9% in the prior year.
• Income from operations saw a substantial rise of 167.9% to $6.67 million.
• The company added 89 net plasma centers and 45 net pharma patient affordability programs over the past year.
• Gross dollar volume loaded on cards increased to $514 million in Q1 2026 from $407 million in Q1 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant year-over-year growth in revenue, net income, and operational performance, indicating robust business momentum.

Positives

• Significant revenue growth of 50.8% year-over-year, reaching $28.04 million.
• Net income more than doubled, increasing by 110.3% to $5.44 million.
• Strong improvement in gross profit (55.8%) and gross margin (65.0%).
• Exceptional growth in income from operations (167.9%).
• Expansion of plasma centers by 89 and pharma patient affordability programs by 45.
• Increased gross dollar volume loaded on cards by 26.3% to $514 million.
• Improved revenue conversion rates to 5.45% and gross profit conversion rates to 3.54% of gross dollar volume loaded on cards.

Negatives

• Accounts receivable increased significantly by $22.06 million, partly due to timing of pass-through payments.
• Selling, general and administrative expenses increased by 20.5% to $8.91 million, driven by compensation, stock-based compensation, and technology investments.
• Depreciation and amortization expense increased by 46.4% due to amortization of intangible assets from the Gamma acquisition and software development.

Risks

• Potential for losses if a financial institution holding deposits were to be placed into receivership, although the company has not experienced losses and uses deposit swapping programs.
• The company may become involved in various lawsuits and legal proceedings that could harm its business.
• Reliance on third-party software for specialized business functions that may not be developed internally within time and budget constraints.
• The company's financial position and ability to operate could be adversely affected if it is unable to access its cash and cash equivalents as needed.

Future Outlook

The company plans to continue investing in technology improvements, sales and marketing, cybersecurity, fraud prevention, customer service, and regulatory compliance throughout 2026. Management believes its current cash position and forecasted revenues and cash flows will be sufficient to sustain operations for the next twenty-four months. The company also periodically evaluates raising capital to diversify into new market verticals, but believes it can support existing business and expand using internally generated funds if new capital is not raised.

Management Comments

• Management believes its distinctive positioning allows it to provide end-to-end technologies that securely manage transaction processing, cardholder enrollment, value loading, account management, data and analytics, and customer service.
• Management believes its architecture is known for its cross-platform compatibility, flexibility, and scalability, allowing clients and partners to leverage these advantages for cost savings and revenue opportunities.
• Management believes its available cash on hand, excluding restricted cash, along with its forecast for revenues and cash flows for the remainder of 2026 and through the first quarter of 2028, will be sufficient to sustain operations for the next twenty-four months.
• Management believes that from time to time they evaluate raising capital to enable diversification into new market verticals, and if new capital is not raised, they believe they will still be able to support existing business and expand into new vertical markets using internally generated funds.

Industry Context

StockSavvy.ai notes that Paysign's strong performance in the first quarter of 2026, particularly its revenue growth in the pharma and plasma industries, aligns with broader trends in specialized payment solutions and patient affordability programs. The company's focus on technology and platform integration appears to be a key differentiator in a competitive fintech landscape.

Comparison to Industry Standards

• Paysign's revenue growth of 50.8% in Q1 2026 significantly outpaces the average revenue growth for payment processing companies, which has been in the mid-to-high single digits in recent periods.
• The company's net income margin of 19.4% in Q1 2026 is strong compared to many fintech and payment processors, which often operate on thinner margins.
• The increase in Gross Dollar Volume (GDV) loaded on cards to $514 million demonstrates significant transaction volume, a key indicator of market penetration and platform adoption within the prepaid card sector.
• Paysign's revenue conversion rate of 5.45% and gross profit conversion rate of 3.54% suggest efficient monetization of transaction volumes, potentially outperforming industry averages where fees can be more competitive.

Legal Proceedings

• The company is not currently a party to any pending or threatened legal proceedings that it believes could have a material adverse effect on its business or financial condition.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong financial performance and growth, supported by a new stock repurchase program.
• Employees: Continued investment in hiring and employee retention, with increased stock-based compensation, suggests a focus on human capital.
• Customers: Expansion of pharma patient affordability programs and plasma center services indicates continued support and growth for these client segments.
• Suppliers/Partners: Increased transaction volumes and program growth may lead to increased business for third-party service providers and network partners.

Next Steps

• Continue investing in technology improvements, sales and marketing, cybersecurity, fraud prevention, customer service, and regulatory compliance throughout 2026.
• Monitor and manage cash position and forecast revenues and cash flows to sustain operations for the next twenty-four months.
• Periodically evaluate opportunities to raise capital for diversification into new market verticals.

Key Dates

Recommendation

The Q1 2026 results demonstrate exceptional growth across key financial metrics, including revenue, net income, and operational income, significantly exceeding prior year performance. The expansion in core business segments (pharma and plasma) and improved conversion rates, coupled with a positive future outlook and ongoing investment in technology and growth, present a compelling case for strong future performance. The company's financial health appears robust, supporting a 'strong buy' recommendation.

Keywords

Paysign, 10-Q, Quarterly Report, Prepaid Cards, Payment Processing, Pharma Affordability, Plasma Industry, Financial Results, Revenue Growth, Net Income